Highlights From CROI 2022
Research was presented virtually at CROI 2022, the annual Conference on Retroviruses and...
Read More
Meeting Coverage
Novel Regimen May Avoid TME Surgery in Rectal Cancer
In patients with rectal cancer, neoadjuvant radiotherapy (RT) followed by atezolizumab and...
Read More
IMbrave 151 Missed Primary Endpoint in Advanced BTC
Adding bevacizumab to atezolizumab plus cisplatin and gemcitabine did not significantly improve...
Read More
New Standard of Care for Colorectal Cancer
The phase 3 SUNLIGHT trial demonstrated that bevacizumab plus trifluridine/tipiracil (FTD/TPI)...
Read More
SWOG 1815, First-Ever Phase 3 Trial in BTC, Fails
The triplet regimen of nab-paclitaxel plus gemcitabine plus cisplatin (GCN) did not improve the...
Read More
Sorafenib Plus TACE May Control HCC After Resection
The postoperative adjuvant combination therapy of sorafenib plus transarterial chemoembolization...
Read More
Nanvuranlat Prolongs PFS in Refractory Advanced BTC
Patients with pre-treated, advanced biliary tract cancer (BTC) may benefit from treatment with...
Read More
New First-Line Option for Metastatic Pancreatic Duct Cancer
The phase 3 NAPOLI-3 trial showed that liposomal irinotecan plus 5-fluorouracil/leucovorin and...
Read More
Zolbetuximab Plus mFOLFOX6 Scores in Gastric Cancer
Zolbetuximab added to mFOLFOX6 improved the progression-free survival (PFS) and overall survival...
Read More
ASH 2022: Leukemia eBook
Focus on ASH Leukemia 2023.indd
Read More
Palliative Radiation Therapy Improves Hepatic Pain in HCC & Liver Metastases
Single fraction radiation therapy (RT) outperformed best supportive care in reducing hepatic pain...
Read More
ASCO GI Continuing Education
The Gastrointestinal Cancers Symposium will focus on multidisciplinary care that will highlight...
Read More
Industry Expert Theater
Thursday, January 19 Time: 12:15 PM – 1:00 PM Location: Posters, Exhibits, and Food Room...
Read More
Schedule At A Glance
Thursday, January 19, 2023 7:00 AM-8:00 AM Complimentary Continental Breakfast 7:00 AM-5:45 PM...
Read More
IMbrave150: Exploratory Effectiveness and Safety in Unresectable HCC Patients Treated with Atezo Past Radiological Progression
Therapy with atezolizumab (atezo) plus bevacizumab (bev) in systemic treatment (tx)-naive patients...
Read More
Atezolizumab Plus Bevacizumab in Real-world Settings for HCC and Child-Pugh A and B Cirrhosis Patients
Atezolizumab plus bevacizumab (A+B) is the new standard of care for first-line treatment of...
Read More
Treatment and Outcomes for Patients with Hepatocellular Carcinoma Treated at a Single Center
In the treatment of hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) based...
Read More
The Effects of Immunotherapy on HCC Patients with Nonalcoholic Steatohepatitis Cirrhosis
Hepatocellular carcinoma (HCC) is the most rapidly expanding cause of cancer-related mortality in...
Read More